Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT04483206
Recruiting
Personalized Autologous Transplant for Multiple Myeloma
Phase 1 · United States · 2 sites
Registry update: 15 Jun 2026
NCT04822337
Recruiting
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Phase 1/2 · United States · 2 sites
Registry update: 26 Oct 2026
NCT04533217
Recruiting
Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.
Not applicable · Denmark · 1 site
Registry update: 3 Dec 2024
NCT04661137
Recruiting
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Phase 2 · United States · 2 sites
Registry update: 21 Sept 2026
NCT05001087
Recruiting
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
Not applicable · Italy · 27 sites
Registry update: 9 Sept 2026
NCT04776330
Recruiting
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Phase 1/2 · China · 1 site
Registry update: 25 Feb 2025
NCT04566328
Recruiting
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · Puerto Rico, United States · 647 sites
Registry update: 19 Aug 2026
NCT04888741
Recruiting
Methods of T Cell Depletion Trial (MoTD)
Phase 2 · United Kingdom · 17 sites
Registry update: 5 May 2026
NCT04634552
Recruiting
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2 · Belgium, China, Germany, Spain, France, Israel, Japan, South Korea, Netherlands, Poland, United States · 75 sites
Registry update: 3 Nov 2026
Conflicting statuses (updated in the registry within the last month)
NCT04643002
Recruiting
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Phase 1/2 · Australia, Germany, France, Greece, Israel, Italy, South Korea, Norway, United States · 25 sites
Registry update: 13 Oct 2026
NCT04349358
Recruiting
FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)
Phase 2 · France · 3 sites
Registry update: 17 Oct 2023
Conflicting statuses (not updated in the registry for 36 months)
NCT04645199
Recruiting
National Longitudinal Cohort of Hematological Diseases
Not applicable · China · 1 site
Registry update: 12 Feb 2026
2024-513033-21-00
Recruiting
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Phase 1 · Spain, France, Italy, Netherlands · 4 sites
Registry update: 14 Aug 2026
NCT04314752
Recruiting
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
Not applicable · United States · 1 site
Registry update: 14 Sept 2026
NCT04513639
Recruiting
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Phase 2/3 · Lithuania, Norway · 14 sites
Registry update: 20 Mar 2025
Conflicting statuses (not updated in the registry for 19 months)
NCT04504526
Recruiting
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
Early phase 1 · China · 1 site
Registry update: 21 Jul 2026
NCT05968417
Recruiting
Myeloma Novel Drug Discovery Ver 1.2
Not applicable · United Kingdom · 1 site
Registry update: 3 Aug 2023
NCT05556928
Recruiting
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
Not applicable · United States · 1 site
Registry update: 8 Dec 2025
NCT04414475
Recruiting
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Phase 2 · Greece, Israel · 15 sites
Registry update: 29 Oct 2026
NCT04300998
Recruiting
Study of CAR-T Therapy in Older Patients
Not applicable · United States · 1 site
Registry update: 7 Apr 2026

Ordered by registry start date. Freshness and sponsorship never change the order.